Nondisposable materials, chronic inflammation, and adjuvant action.
Why inflammatory responses become chronic and how adjuvants work remain unanswered. Macrophage-lineage cells are key components of chronic inflammatory reactions and in the actions of immunologic adjuvants. One explanation for the increased numbers of macrophages long term at sites of chronic inflammation could be enhanced cell survival or even local proliferation. The evidence supporting a unifying hypothesis for one way in which this macrophage survival and proliferation may be promoted is presented. Many materials, often particulate, of which macrophages have difficulty disposing, can promote monocyte/macrophage survival and even proliferation. Materials active in this regard and which can initiate chronic inflammatory reactions include oxidized low-density lipoprotein, inflammatory microcrystals (calcium phosphate, monosodium urate, talc, calcium pyrophosphate), amyloidogenic peptides (amyloid beta and prion protein), and joint implant biomaterials. Additional, similar materials, which have been shown to have adjuvant activity (alum, oil-in-water emulsions, heat-killed bacteria, CpG oligonucleotides, methylated bovine serum albumin, silica), induce similar responses. Cell proliferation can be striking, following uptake of some of the materials, when macrophage-colony stimulating factor is included at low concentrations, which normally promote mainly survival. It is proposed that if such responses were occurring in vivo, there would be a shift in the normal balance between cell survival and cell death, which maintains steady-state, macrophage-lineage numbers in tissues. Thus, there would be more cells in an inflammatory lesion or at a site of adjuvant action with the potential, following activation and/or differentiation, to perpetuate inflammatory or antigen-specific, immune responses, respectively.
Hamilton
John A
JA
Arthritis and Inflammation Research Centre and Cooperative Research Centre for Chronic Inflammatory Diseases, University of Melbourne, Department of Medicine, The Royal Melbourne Hospital, Parkville, Australia. jahami@unimelb.edu.au
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology; D002455:Cell Division; D002470:Cell Survival; D002908:Chronic Disease; D005487:Foam Cells / Q000502:physiology; D007249:Inflammation / Q000209:etiology* / Q000276:immunology; D008077:Lipoproteins, LDL / Q000378:metabolism; D008264:Macrophages / Q000276:immunology; D019636:Neurodegenerative Diseases / Q000209:etiology
D000276:Adjuvants, Immunologic; D000682:Amyloid; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein